The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. Content within the patient forum is user-generated and has not been reviewed by medical professionals. Other sections of the Melanoma Research Foundation website include information that has been reviewed by medical professionals as appropriate. All medical decisions should be made in consultation with your doctor or other qualified medical professional.

Melanoma Molecular Disease Model

This topic has 10 replies, 5 voices, and was last updated 13 years, 11 months ago by boot2aboot.

Post

- October 2, 2011 at 8:50 am
- Quote
JerryfromFauq
Participant
This is a great article that discuses melanoma signaling pathways, the molecular drivers of this disease, molecular subtypes and developing proposed treatment guidelines for each subtype, including specific assays, drugs, and clinical trials. labs that conduct various tests, etc. This information is written at a laymans level and is fairly easy to follow.

This is a great article that discuses melanoma signaling pathways, the molecular drivers of this disease, molecular subtypes and developing proposed treatment guidelines for each subtype, including specific assays, drugs, and clinical trials. labs that conduct various tests, etc. This information is written at a laymans level and is fairly easy to follow.

Drug Company Status Clinical Trial Target

I have only posted the Abstract here. The real meat is at the URL.

http://mmdm.cancercommons.org/ml/index.php/A_Melanoma_Molecular_Disease_…

I. Abstract

While advanced melanoma is one of the most challenging cancers to treat, recent developments in our understanding of the molecular drivers of this disease have uncovered exciting opportunities to guide personalized therapy decisions. Genetic analysis of melanoma have uncovered several key molecular pathways that are involved in disease onset, progression as well as prognosis. These advances now make possible classification of melanoma into molecular subtypes (unlike traditional histological subtypes), with proposed treatment guidelines for each subtype, including specific assays, drugs, and clinical trials.

This paper outlines such a 'molecular disease model' that can be used by both researchers and clinicians- clinicians could use it a guide in their therapy decisions and contribute to it with real-life patient outcomes data whereas researchers could refine molecular subtypes based on their findings and use clinical outcomes data to guide their research. This 'dynamic' paper will reflect latest scientific, clinical and technological advancements by providing a rapid process for submission, contextualization and dissemination of information and data.

Viewing 7 reply threads

Replies

- - October 2, 2011 at 2:57 pm
  - Quote
  jim Breitfeller
  Participant
  Jerry,
  
  Thanks for this paper.
  
  Jimmy B
- - October 2, 2011 at 2:57 pm
  - Quote
  jim Breitfeller
  Participant
  Jerry,
  
  Thanks for this paper.
  
  Jimmy B
- - October 2, 2011 at 3:26 pm
  - Quote
  MariaH
  Participant
  Jerry (and Jimmy),
  
  THANK YOU, THANK YOU, THANK YOU……can't stress enough how informative this is. I am forwarding it to a newbie on the board.
  
  Very informational, and maybe now I can understand Jim's diagrams better, instead of staring at them cross eyed.
  
  Keep up the good work you two.
  
  Maria
- - October 2, 2011 at 3:26 pm
  - Quote
  MariaH
  Participant
  Jerry (and Jimmy),
  
  THANK YOU, THANK YOU, THANK YOU……can't stress enough how informative this is. I am forwarding it to a newbie on the board.
  
  Very informational, and maybe now I can understand Jim's diagrams better, instead of staring at them cross eyed.
  
  Keep up the good work you two.
  
  Maria
  - October 3, 2011 at 3:31 am
    
    Quote
    mombase
    Participant
    
    I wish there was a LIKE button!! I have tried so hard to understand the models, with very limited success….
  - October 3, 2011 at 3:31 am
    
    Quote
    mombase
    Participant
    
    I wish there was a LIKE button!! I have tried so hard to understand the models, with very limited success….
- - October 3, 2011 at 6:51 pm
  - Quote
  rbruce
  Participant
  Thanks so much for this. I am seeing my Oncologist Wednesday about PK13/MTOR and PD-1 trials and this clears up a lot of questions I have. I am NRAS+ and it seems the PK13 pathway inhibitors may work for me. Up until reading this I just felt like they were throwing ideas at me based upon their own trials. UCSF has a PK13/MTOR trial open right now and the ANti-PD-1 trial opens in November. My last scans were August 1st, so I think I'll be able to be scanned very soon to see if I can wait for the PD-1 trial or go for the Pk13 now. Thank you again for sharing.
  
  Robert
- - October 3, 2011 at 6:51 pm
  - Quote
  rbruce
  Participant
  Thanks so much for this. I am seeing my Oncologist Wednesday about PK13/MTOR and PD-1 trials and this clears up a lot of questions I have. I am NRAS+ and it seems the PK13 pathway inhibitors may work for me. Up until reading this I just felt like they were throwing ideas at me based upon their own trials. UCSF has a PK13/MTOR trial open right now and the ANti-PD-1 trial opens in November. My last scans were August 1st, so I think I'll be able to be scanned very soon to see if I can wait for the PD-1 trial or go for the Pk13 now. Thank you again for sharing.
  
  Robert
- - October 3, 2011 at 7:50 pm
  - Quote
  boot2aboot
  Participant
  thankyou for sharing this Jerry
  
  boots
- - October 3, 2011 at 7:50 pm
  - Quote
  boot2aboot
  Participant
  thankyou for sharing this Jerry
  
  boots

Viewing 7 reply threads

Tagged: cutaneous melanoma

You must be logged in to reply to this topic.

The MRF Patient Forum is the oldest and largest online community of people affected by melanoma. It is designed to provide peer support and information to caregivers, patients, family and friends. There is no better place to discuss different parts of your journey with this cancer and find the friends and support resources to make that journey more bearable.

The information on the forum is open and accessible to everyone. To add a new topic or to post a reply, you must be a registered user. Please note that you will be able to post both topics and replies anonymously even though you are logged in. All posts must abide by MRF posting policies.